News
-
Cellular Biomedicine Group Marks The Launch Of Clinical Trial For Knee Osteoarthritis (KOA)
4/3/2013
This week Cellular Biomedicine Group (OTCQB: CBMG) held a ceremony to mark the launch of their clinical trial for haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA).
-
Isis Initiates Phase 1 Study Of ISIS-APOA Rx To Treat Atherosclerosis
4/3/2013
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.
-
Catabasis Initiates Phase 1 Trial Of CAT-2003 For Treatment Of Severe Hypertriglyceridemia
3/26/2013
Catabasis Pharmaceuticals Inc., today announced the initiation of a Phase 1 study to investigate the safety and tolerability of CAT-2003 in healthy volunteers and in adults with mildly elevated lipids. CAT-2003 is a conjugate of niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, covalently linked using the company's proprietary SMART Linker technology to create a new chemical entity and is being developed for patients with severe hypertriglyceridemia.
-
Telormedix Enrols First Patient For Phase II In Bladder Cancer
3/11/2013
Telormedix, a clinical stage biopharmaceutical company focusing on toll-like receptor 7 (TLR7) small molecules in the treatment of cancer and inflammatory diseases, recently announced that it has recruited the first patient in a Phase II trial of its lead product TMX-101, a TLR-7 agonist, in carcinoma in situ (CIS) in the bladder.
-
Anacor Pharmaceuticals Announces Positive Results From The Second Phase 3 Trial Of Tavaborole For Onychomycosis
3/4/2013
Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302). Tavaborole is a topical anti-fungal for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.
-
Sanofi And Regeneron Report Positive Proof-of-Concept Data For Dupilumab
3/4/2013
PARIS and TARRYTOWN, N.Y., March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
-
CeQur Announces Positive Results From Study Evaluating Simple Insulin Delivery Device Among People With Type 2 Diabetes
2/28/2013
CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that initial data from a study of the company's PaQ® Insulin Delivery Device were presented today at the 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France.
-
Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
2/26/2013
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-CRPRx in patients with paroxysmal atrial fibrillation.
-
Cubist Announces Exclusive Option To Acquire Adynxx
2/25/2013
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Adynxx, Inc. announced today that they have entered into an option agreement under which Cubist has the exclusive right to acquire Adynxx following the data readout of Adynxx’s Phase 2 trial for its lead product candidate, AYX1.
-
Adynxx Enrolls First Patient In Phase 2 Proof-Of-Concept Study For AYX1, Lead Compound For The Prevention Of Post-Surgical Pain
2/25/2013
Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced recently that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.